Crizotinib is an orally administered drug for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Despite the impressive efficacy of crizotinib in the treatment of ALK-positive lung cancer, acquired resistance eventually develops in the majority of patients. The microRNA (miR)-200c reverses the resistance of lung cancer cells to various chemotherapeutic drugs and molecular targeted drugs, however, whether it can reverse the resistance of crizotinib remains unknown. The present study established a crizotinib resistant cell line (NCI-2228/CRI), which was derived from the parental NCI-2228 cell line by long-term exposure to increasing concentrations of crizotinib. Through overexpression and suppression of miR-200c expression, the characteristics associated with epithelial-mesenchymal transition (EMT), including morphology, EMT marker proteins and cellular mobility, were investigated. Cell viability and invasion assays demonstrated that high expression of miR-200c significantly inhibited the proliferation, migration and invasion of NCI-2228 cells compared with the negative control. A luciferase reporter assay indicated that miR-200c directly targeted the 3'-untranslated region of zinc finger E-box binding homeobox 1. Additionally, reverse transcription-quantitative polymerase chain reaction analysis demonstrated that the mRNA levels of N-cadherin and Vimentin were decreased in NCI-2228 cells transfected with miR-200c mimic compared with negative control cells, whereas the mRNA level of E-cadherin was increased. In addition, EMT was reversed by miR-200c, which suggests that miR-200c may serve a role in mediating the sensitivity of NCI-2228/CRI cells to crizotinib. The present study may therefore contribute to improving the sensitivity of ALK positive lung cancer cells to crizotinib.
Introduction
Lung cancer is a malignant neoplasm associated with high morbidity and is the leading cause of cancer-associated mortality worldwide (1) . Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases (1) (2) (3) . The majority of patients with NSCLC are elderly at the time of diagnosis (2) . The five-year survival rate for NSCLC is 15%, which is reduced to 4% following the development of metastases (1) , therefore research to prolong survival times for such patients is of vital importance.
Personalized therapy, based on the genetic characteristics of patients, is the most effective method for the treatment of lung cancer (2) . Anaplastic lymphoma kinase (ALK) inhibitors such as crizotinib can be used to treat NSCLC successfully, greatly improving the prognosis of patients with lung cancer that have ALK gene mutations (3) . Crizotinib is a tyrosine kinase inhibitor with activity against ALK, MET proto-oncogene receptor tyrosine kinase and ROS proto-oncogene 1 receptor tyrosine kinase (4) . It was the first molecular targeted drug to undergo clinical development for the treatment of patients with ALK-positive advanced NSCLC, where it exhibited an objective response rate (ORR) of ~60% (5) . Crizotinib has been approved for the treatment of patients with ALK-positive lung cancer by the Food and Drug Administration (6) .
Recently, a clinical trial evaluated the effects of first-line crizotinib vs. pemetrexed-cisplatin in patients with advanced ALK-positive NSCLC and demonstrated that crizotinib resulted in increased progression-free survival and ORR, with fewer side effects (7) . Crizotinib is, therefore, an attractive therapeutic option for patients with ALK-positive lung cancer (7, 8) .
However, in virtually all patients receiving crizotinib therapy, drug resistance occurs within approximately one year,
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HAI-XIANG GAO 1,2 , LI YAN 2 , CHUNZHI LI 3 , LIAN-MEI ZHAO 4 and WEI LIU via complex resistance mechanisms (9) . New approaches for solving drug resistance and delaying its occurrence are therefore required, including investigating methods to increase the sensitivity of conventional treatments, including chemotherapy, radiation therapy and molecular targeted therapy. An important member of the microRNA (miR)-200 family, miR-200c, exhibits low-expression in numerous tumor tissues and can regulate epithelial-mesenchymal transition (EMT), tumor invasion and metastasis (10) (11) (12) . The overexpression of miR-200c in mesenchymal cells can promote mesenchymal-epithelial transition (MET) (11) , and enhance the sensitivity of lung cancer cells to various chemotherapy drugs, epidermal growth factor receptor tyrosine kinase inhibitors and radiotherapy (13) (14) (15) . In addition, previous reports have demonstrated that miR-200c regulates EMT by targeting ZEB1 and ZEB2 (11, 16) . However, whether it can improve the sensitivity of ALK-positive NCI-2228 lung cancer cells to crizotinib is unknown. In the present study, the regulation mechanism of miR-200c in ALK-positive lung cancer cells to crizotinib was investigated. To establish the cr izotinib-resistant cell line, NCI-2228/CR I, 5 m l NCI-2228 cel l susp ension (1x10 6 cells/ml) was seeded in cell culture plates prior to treatment with 80 nM crizotinib (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany) until >70% confluence was reached. The concentration of crizotinib was then increased to 160, 200, 300, 400, 500, 600, 700 and 800 nM on a bi-weekly basis. Following approximately six months of treatment, NCI-2228/CRI cells were resistant to 800 nM crizotinib. Cell viability and invasion assays. Cell viability was determined using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. Cells in RPMI1640 culture medium were first seeded onto 96-well plates at a density of 5x10 3 cells/well and cultured for 24 h. The medium was then replaced with serum-free fresh medium plus crizotinib. NCI-2228 cells were treated with 0, 12.5, 25, 50, 100 and 200 nM crizotinib, whereas the drug-resistant NCI-2228/CRI cells were treated with 0, 800, 1,600, 2,000, 4,000 and 8,000 nM crizotinib. Following 48 h incubation, 100 µl MTT was added to each well and the cells were incubated for a further 4 h. The medium was subsequently discarded before 100 µl of 10% sodium dodecyl sulfate (SDS) was added into each well, and the absorbance was read at 492 nm using the Multiskan FC Microplate Photometer (Thermo Fisher Scientific, Inc.). The half maximal inhibitory concentration (IC 50 ) was calculated using SPSS (SPSS, Inc., Chicago, IL, USA). All experiments were performed in triplicate.
Materials and methods

Cell
Cell transfection.
The invasion assay was performed using Transwell inserts in 24-well dishes as described previously (17) . For each Transwell, the number of migrated cells in five random fields of view were counted using a light microscope.
RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA of cells was extracted using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocols. Total RNA (1 µg) was used to generate the first strand cDNA using RevertAid™ First Strand cDNA Synthesis kit (Fermentas; Thermo Fisher Scientific, Inc., Waltham, MA, USA), for 1 h at 42˚C. qPCR reactions were performed using Go Taq ® Green Master Mix (Promega Corporation, Madison, WI, USA) according to the manufacturer's protocol. Thermal cycling conditions were as follows: Denaturation for 2 min at 95˚C followed by 40 cycles of 95˚C for 15 sec, 60˚C for 1 min and 72˚C for 1-2 min. The mRNA expression levels of GAPDH were used as the internal control. The relative expression levels of each target gene were calculated using the 2 -ΔΔCq method (18) . Sequences for the PCR primers used are presented in Table I .
Luciferase reporter assay. The 3'-untranslated region (UTR) for zinc finger E-box binding homeobox 1 (ZEB1) was PCR-amplified from genomic DNA as described previously (19) , and inserted downstream of the firefly luciferase gene in the pmiR-REPORT or the pmiR control plasmid (Applied Biosystems; Thermo Fisher Scientific, Inc.). The PCR primers used to amplify the ZEB1 3'-UTR are presented in Table I . NCI-2228 cells were co-transfected with 2 µg of the firefly luciferase reporter vector and 0.5 µg of the control pRL-TK vector containing Renilla luciferase (Promega Corporation) using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. For each group, 20 nM of the miR-200c mimic or miR-200c mimic negative control was used. Following 48 h transfection, cells were lysed by incubating with 500 µl lysis buffer (Promega Corporation) for 15 min. The firefly and Renilla luciferase activities were then measured using the GloMax 96 Microplate Luminometer (Promega Corporation) and the Dual-Luciferase Reporter assay system (Promega Corporation) according to the manufacturer's protocols.
Western blot analysis. Transfected cells were harvested for immunoblot analysis following 72 h incubation. Cells were lysed in lysis buffer (Beyotime Institute of Biotechnology, Jiangsu, China). The protein concentration of cell lysates was determined by using Bio-Rad Protein Assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA) according to the manufacturer's protocols. Proteins (15 µg) were separated by SDS-polyacrylamide gel electrophoresis on 10-15% gels and transferred to polyvinylidene fluoride membranes. Membranes were blocked with 8% non-fat dry milk for 1 h at room temperature before they were immunoblotted overnight at 4˚C with the following primary antibodies: Glyceraldehyde 3-phosphate dehydrogenase (GAPDH; dilution, 1:1,000; cat. no. 10494-1-AP; ProteinTech Group, Inc., Chicago, IL, USA), E-cadherin (dilution, 1:1,000; cat. no. 20874-1-AP; ProteinTech Group, Inc.), N-cadherin (dilution, 1:1,000; cat. no. 13769-1-AP; ProteinTech Group, Inc.), Vimentin (dilution, 1:1,000; cat. no. 10366-1-AP; ProteinTech Group Inc.) and CD24 (dilution, 1:1,000; cat. no. 18330-1-AP; ProteinTech Group, Inc.), ZEB1 (dilution, 1:2,000; cat. no. sc-25388; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and ZEB2 (dilution, 1:2,000; cat. no. sc-48789; Santa Cruz Biotechnology, Inc.). After washing three times with phosphate-buffered saline plus 0.05% Tween-20, the membrane was incubated with the horseradish peroxidase-conjugated IgG secondary antibody (dilution, 1:1,000; cat. no. RPN4301; GE Healthcare Life Sciences, Shanghai, China) for 2 h at room temperature. Signals were detected with UltraECL Western Blot Detection reagent (Beyotime Institute of Biotechnology) and images visualized on Kodak film (Kodak, Rochester, NY, USA) and quantified with Quantity One Software version 4.4 (Bio-Rad Laboratories Inc.). All experiments were performed in triplicate.
Statistical analysis. All data are expressed as the mean ± standard deviation. All analysis was performed using SPSS version 13.5 (SPSS, Inc.). Comparisons of continuous measurement data were conducted with Student's t-test. Comparisons among treatment groups and controls were conducted using one-way analysis of variance with a post-hoc Tukey test. P<0.05 was considered to indicate a statistically significant difference.
Results
Crizotinib reduces lung cancer cell viability of NCI-2228.
Assessment of cell viability by MTT assay revealed that crizotinib significantly inhibited the proliferation of NCI-2228 cells in vitro in a dose-dependent manner compared with untreated control cells (5 nM, P=0.016; 10 nM, P=0.001; 20 nM, P=0.002), but had only a weak inhibitory effect on the viability of A549 and H640 cells compared with untreated control (Fig. 1) . Fig. 2A and B) . Cell viability (Fig. 2C and D) and invasion assays ( 
miR-200c inhibits proliferation, migration and invasion of
Increased miR-200c reverses EMT in NCI-2228 cells.
To further examine the regulation of miR-200c expression in NCI-2228 cells, the miR-200c was overexpressed through transfection with miR-200c mimic, and the mRNA (Fig. 4A) and protein (Fig. 4B) Fig. 5A and B) . Furthermore, the NCI-2228/CRI cells displayed a certain degree of resistance to the ALK inhibitor LDK378 and chemotherapeutic drugs, paclitaxel and cisplatin (data not shown). NCI-2228/CRI cells exhibited increased invasion rates compared with NCI-2228 (P=0.035; Fig. 5C ) and appeared spindle-shaped compared to the oval shape of NCI-2228 cells (Fig. 5D ). In addition, the relative expression of miR-200c in NCI-2228/CRI cells was also demonstrated to be reduced by 24.93-fold when compared with NCI-2228 cells (P=0.014; Fig. 5E ).
EMT occurs in NCI-2228/CRI cells.
To elucidate the resistance mechanism of NCI-2228/CRI cells to crizotinib, the mRNA (Fig. 6A) and protein ( Fig. 6B ) expression levels of epithelial and mesenchymal cell markers were analyzed. The mRNA expression levels of N-cadherin and Vimentin were increased in NCI-2228/CRI cells compared with the parental cell line (P=0.004 and P=0.013, respectively; Fig. 5A ), while E-cadherin was decreased in NCI-2228/CRI cells (P=0.017; Fig. 5A ). The same trends in protein expression were also observed (Fig. 6B ). In addition, the mRNA levels of ZEB1 and ZEB2 (transcription factors involved in EMT) were increased in NCI-2228/CRI cells compared with NCI-2228 (P=0.009 and P=0.003, respectively; Fig. 6A ), with increased protein expression similarly observed by western blotting (Fig. 6B) . The present study, therefore, suggests that EMT occurs in NCI-2228/CRI cells. 
Discussion
It is widely accepted that the miR-200 family are involved in the proliferation, invasion, metastasis and drug resistance of various types of tumor (19) (20) (21) (22) (23) (24) (25) (26) . As an important member of the miR-200 family, miR-200c displays low expression in numerous tumor tissues, and can regulate EMT, tumor invasion and metastasis (10) (11) (12) . However, few studies examining the effect of miR-200c in the resistance of crizotinib have been conducted. The present study reported that miR-200c expression was significantly lower in NCI2228/CRI cells compared with NCI2228 cells, suggesting that miR-200c may be associated with resistance to crizotinib. EMT is associated with acquired crizotinib resistance (27, 28) . In the present study, overexpression of miR-200c was demonstrated to increase the expression of E-cadherin, and decrease the expression of Vimentin and N-cadherin. The results indicated that EMT was reversed in NCI-2228. In addition, morphological changes to the spindle-cell shape of NCI-2228 were observed in NCI-2228/CRI cells compared with parental cells, and were accompanied by a decrease in E-cadherin, and increase in N-cadherin and Vimentin expression, indicating the occurrence of EMT in NCI-2228/CRI cells. Furthermore, invasion and migration capabilities were Moreover, NCI-2228/CRI cells exhibited resistance to conventional chemotherapy drugs, such as paclitaxel, cisplatin and the next-generation ALK tyrosine kinase inhibitor LDK378, which is similar to the previous report (data not shown) (28) . The changes to EMT marker expression levels also suggested that EMT is involved in resistance to drugs, including chemotherapeutics and molecular targeted drugs (28, 29) .
Drug resistance mechanisms are divided into pharmacological and biological mechanisms (9) . Regulation of EMT by miR-200c has been previously demonstrated to be mediated by a negative feedback loop targeting ZEB1 or ZEB2 (11, 30) . ZEB1 and ZEB2 mediate EMT by repressing the transcription of E-cadherin in order to enhance cell migration and invasion (31-33). The present study examined the mechanism by (E) Total RNA was extracted from NCI-2228 and transfected NCI-2228/CRI cells, and subjected to RT-qPCR. GAPDH was used as an internal control. (F) Cell lysates from NCI-2228 or transfected NCI-2228/CRI were subjected to western blot analysis, and (G) the relative protein levels of N-cadherin, Vimentin, E-cadherin and CD24 were analyzed using GAPDH as the loading control. Values are presented as the mean ± standard deviation of three independent experiments. 
